Millennium Management LLC cut its stake in shares of National Research Co. (NASDAQ:NRC - Free Report) by 64.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 81,961 shares of the company's stock after selling 149,637 shares during the period. Millennium Management LLC owned about 0.35% of National Research worth $1,446,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in the stock. Principal Financial Group Inc. increased its stake in shares of National Research by 10.7% in the 4th quarter. Principal Financial Group Inc. now owns 12,018 shares of the company's stock worth $212,000 after purchasing an additional 1,161 shares in the last quarter. MetLife Investment Management LLC increased its stake in shares of National Research by 28.7% in the 4th quarter. MetLife Investment Management LLC now owns 11,630 shares of the company's stock worth $205,000 after purchasing an additional 2,592 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of National Research by 35.0% in the 4th quarter. SG Americas Securities LLC now owns 7,298 shares of the company's stock worth $129,000 after purchasing an additional 1,893 shares in the last quarter. American Century Companies Inc. increased its stake in shares of National Research by 8.1% in the 4th quarter. American Century Companies Inc. now owns 39,254 shares of the company's stock worth $692,000 after purchasing an additional 2,956 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in shares of National Research by 37.7% in the 4th quarter. Deutsche Bank AG now owns 18,431 shares of the company's stock worth $325,000 after purchasing an additional 5,048 shares in the last quarter. 47.26% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other news, major shareholder Patrick E. Beans bought 2,500 shares of the company's stock in a transaction that occurred on Monday, May 12th. The stock was bought at an average price of $13.59 per share, with a total value of $33,975.00. Following the acquisition, the insider now owns 35,003 shares of the company's stock, valued at approximately $475,690.77. This represents a 7.69% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 8.10% of the stock is currently owned by insiders.
National Research Stock Performance
Shares of NASDAQ:NRC traded up $0.65 during midday trading on Friday, hitting $15.02. The company had a trading volume of 108,126 shares, compared to its average volume of 96,299. The company has a debt-to-equity ratio of 1.30, a current ratio of 0.47 and a quick ratio of 0.47. The company has a market cap of $342.23 million, a price-to-earnings ratio of 14.30 and a beta of 0.34. National Research Co. has a 12-month low of $9.76 and a 12-month high of $27.07. The company has a fifty day moving average of $12.52 and a two-hundred day moving average of $15.37.
National Research (NASDAQ:NRC - Get Free Report) last posted its quarterly earnings data on Monday, April 28th. The company reported $0.25 EPS for the quarter. The firm had revenue of $33.55 million during the quarter. National Research had a return on equity of 66.52% and a net margin of 17.32%.
National Research Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, July 11th. Investors of record on Friday, June 27th will be issued a $0.12 dividend. This represents a $0.48 annualized dividend and a yield of 3.20%. The ex-dividend date of this dividend is Friday, June 27th. National Research's dividend payout ratio is currently 46.60%.
About National Research
(
Free Report)
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty.
See Also
Before you consider National Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and National Research wasn't on the list.
While National Research currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
